Plain English Summary
Background and study aims
Antibiotics are vitally important medicines. They are used to treat infections caused by bacteria, some of which would kill the person affected. In recent years, however, antibiotic resistance, a situation where an antibiotic no longer works against one or more bacteria, has become a major problem. It has been caused by a number of factors, including general practitioners (GPs) prescribing them for minor illnesses that do not need them or for conditions that antibiotics cant cure (such as the common cold). Here, we are going to test whether sending out letters designed with behavioural science techniques to GPs in practices known to have high antibiotic prescription rates (prescribe a lot of antibiotics) will encourage them to prescribe fewer of them.
Who can participate?
GPs in practices in England whose antibiotic prescribing rate is in the top 20% for their NHS Local Area
What does the study involve?
GP practices are randomised into one of two groups. GPs in group 1 are sent a letter designed to reduce prescription rates. It is sent by the governments Chief Medical Officer and contains some key messages about the importance of antibiotic resistance, levels of antibiotic prescribing, and importantly, simple actions that they can take to reduce the risk of resistance. GPs in group 2 are not sent a letter. Antibiotic prescription rates between the two groups are then measured.
What are the possible benefits and risks of participating?
Benefits of taking part are support and motivation to improve clinical practice by reducing the risk of antibiotic resistance and prolonging the effectiveness of antibiotics in the future. The benefits to GPs are that information about levels of prescribing of antibiotics, resources to facilitate improved prescribing, and simple actions that can be implemented should enable and support them to improve their clinical practice. The risks are minimal because increased awareness and concern about antibiotic resistance is expected and necessary given the serious and growing threat to our health. Careful thought has gone into the content of the letter to make it enabling and supportive rather than negative.
Where is the study run from?
Public Health England (UK)
When is the study starting and how long is it expected to run for?
September 2014 to February 2015
Who is funding the study?
Public Health England (UK)
Who is the main contact?
Dr Tim Chadborn
tim.chadborn@phe.gov.uk
Trial website
Contact information
Type
Scientific
Primary contact
Dr Tim Chadborn
ORCID ID
Contact details
Science and Strategic Information
Health and Wellbeing Directorate
Public Health England
Skipton House
3rd Floor
London Road
London
SE1 6LH
United Kingdom
-
tim.chadborn@phe.gov.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
TP2014015
Study information
Scientific title
Contacting GPs to reduce unnecessary prescriptions of antibiotics: a randomised controlled trial
Acronym
Study hypothesis
A letter designed with behavioural science techniques and sent to GPs in practices with high antibiotic prescribing rates will reduce the antibiotic prescription rates of those GP practices as a whole. Practices randomised to receive the letter will have lower antibiotic prescription rates than practices that do no receive anything.
Ethics approval
NRES Committee London Harrow, 19/09/2014, ref. 14/LO/1544
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
GP practices
Trial type
Prevention
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Antibiotic resistance
Intervention
1,500 GP practices with high antibiotic prescribing rates are randomly allocated into one of two treatment arms:
1. Experiment arm: a letter designed with behavioural science techniques and sent to all GPs in the practice
2. Control arm: no letter is sent
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measures
Our primary outcome measure is a comparison of the change in the antibiotic prescribing rate from September to October 2014 between treatment and control groups, controlling for changes between these two months experienced by GP practices in previous years.
Secondary outcome measures
We will look at prescription rates for specific classes of antibiotics used to treat upper respiratory tract infections: pencillins, macrolides, Coamoxiclav, tetracyclines. This analysis will include looking at changes in the number of doses of specific types antibiotics generally prescribed for upper respiratory tract infections per 1,000 registered patients and whether the intervention has a stronger or weaker effect depending on the location, age, and gender of the recipients. We will compare changes in the antibiotic prescribing rate from September to October 2014 controlling for changes in prescribing between the same two months in 2013 as there is a three-month lag in the publication of the data, we will receive the data to the end of October 2014 in January.
Overall trial start date
29/09/2014
Overall trial end date
27/02/2015
Reason abandoned
Eligibility
Participant inclusion criteria
1. GP practices in England who issued prescriptions in May 2014, according to HSCIC prescribing data (the latest data available at the time of design)
2. GP practices whose antibiotic prescribing rate is in the top 20% for their NHS Local Area, controlling for relevant patient characteristics. More specifically, we will apply the Health and Social Care Information Centre's STARPU weightings for oral antibiotics (BNF 5.1 subset). These consist of age and gender weightings.
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Approximately 1,500 GP practices are randomised (letters sent to 13,300 GPs)
Participant exclusion criteria
1. GP practices are excluded if their current level of prescription (doses per 1000 head of population) is classed as an outlier. The cut-off for outliers is made at the 95th percentile of the distribution, since figures above this level were considered to be the result of measurement error. This judgment was made based on medical advice.
2. We exclude practices that have been in operation for less than a year in September 2014, since we require data for September 2013 in order to apply the difference-in-differences analysis.
Recruitment start date
29/09/2014
Recruitment end date
27/02/2015
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Public Health England
London
SE1 6LH
United Kingdom
Sponsor information
Organisation
Public Health England (UK)
Sponsor details
c/o Dr Elizabeth Coates
Head of Research Governance RDD
Public Health England
Porton
Salisbury
SP5 0JG
United Kingdom
-
elizabeth.coates@phe.gov.uk
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
Public Health England (UK)
Alternative name(s)
PHE
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/26898856